✨ Free AI Report
Aclaris Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Aclaris Therapeutics, Inc.
Research Preview

Aclaris Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significa...

Analyst-debate audio for Aclaris Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aclaris Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aclaris Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech positioned to derisk key immuno-inflammatory programs through 2026 with multiple data readouts...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immuno-inflammatory Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aclaris Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aclaris Therapeutics, Inc. Overview

Pro stress-test →

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significant unmet needs in dermatology and immunology with both small-molecule and biologic candidates.

Strategic Profile

Pro stress-test →

The company achieved strong business execution in 2025 with continued momentum across programs, and 2026 has started with derisking events for two key programs (ITK and ATI-052). Aclaris maintains a strong cash position with several meaningful catalysts expected across its biologics and ITK pipeline this year.

Competitive Landscape

Pro stress-test →

Aclaris competes in the immuno-inflammatory therapeutics space against companies developing JAK inhibitors, monoclonal antibodies, and ITK inhibitors. Key competitive programs include ritlecitinib (Pfizer, alopecia areata) and various TSLP-targeting biologics. Aclaris differentiates through its bispecific ATI-052 platform combining dual pathway inhibition and its proprietary ITK-selective inhibitor technology.

Industry Context

Aclaris Therapeutics, Inc. operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics.

Key facts

Founded: 2016 · Headquarters: Wayne, PA · Revenue: $1.30M · Market cap: $339.14M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aclaris Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Aclaris Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RitlecitinibJAK inhibitor for alopecia areata→DupilumabAnti-IL-4R monoclonal antibody for atopic dermatitis and asthma→TezepelumabAnti-TSLP monoclonal antibody for asthma→

Compare Aclaris Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aclaris Therapeutics, Inc. operates in Biopharmaceuticals - Immuno-inflammatory Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immuno-inflammatory Therapeutics research →
NEW · MCP server

Ask your AI assistant about Aclaris Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aclaris Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aclaris Therapeutics, Inc. do this quarter?”
“Is Aclaris Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aclaris Therapeutics, Inc. do?+
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases. The company is advancing a multi-program pipeline targeting significa...
What is Aclaris Therapeutics, Inc.'s Cyborg Score?+
Aclaris Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aclaris Therapeutics, Inc.'s main competitors?+
Named competitors include Ritlecitinib, Dupilumab, Tezepelumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Aclaris Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aclaris Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aclaris Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.